Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines

CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research (AACR 2018), taking place April 14-18, 2018 in Chicago, IL.

Poster 15: “Neoantigen identification using the ATLAS T cell profiling platform highlights the need to empirically define neoantigens”
Vaccines Session 1, Immunology Track
Sunday, April 15, 2018 from 1 pm to 5 pm CDT
Link to abstract

Poster 5718: “Ex vivo ATLAS-identification of neoantigens for personalized cancer immunotherapy in mouse melanoma”
Neoantigens in Cancer Session, Immunology Track
Wednesday, April 18, 2018 from 8 am to 12 pm CDT
Link to abstract

About Genocea Biosciences, Inc.
Genocea’s mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.

Contact:
Jennifer LaVin
207-360-0473
[email protected]